Title: Role of personalized immunotherapy with dendritic cell exosomes, in COMBINED THERAPY for Cancer: ONCOVIX Program

Abstract:

Introduction Combined Therapy (cancer treatments with different therapeutics mechanisms) is positioned as the new therapeutic way; obtaining results with higher overall survival and higher disease-free survival rates. It is in this context, where the immunotherapy incorporates powerful anti-tumor mechanisms, and even more so in its biological variant, of pulsed dendritic cells, with a very low rate of adverse reactions and highly customizable, whose biotechnology obtained the Nobel Prize in 2011 and FDA approval since 2010 . Conclusion Immunotherapy with pulsed dendritic cells allows new anti-tumor mechanisms not included in conventional therapies such as surgery or chemotherapy, corresponding to the recovery, correction, enhancement or installation of anti-tumor mechanisms by our own immunity, valid in solid tumors and leukemias (in newest versions), age and progression phase, which in turn is enhanced with target therapies. It is developed essentially from a blood sample from the patient and a biopsy sample of the cancer to be treated. It is a feasible, validatable, perfectible treatment, of safe application and reasonable effectiveness, especially in its 3rd generation (or next generation), 15 to 20 times more effective than the 1st generation, with specific management of molecular signals 1, 2 and 3 of type 1 immunopolarization of CD4 + T cells and efficient cytotoxic responses of cytotoxic CD8 + T cells (CTL), thus ensuring antitumor programming and avoiding immune weakening or immunosuppression. The greater complementary effectiveness of pulsed dendritic cell immunotherapy is favored by a use close to the diagnosis of cancer, reduction of tumor mass prior or simultaneous with conventional therapies (surgery, chemo and radiotherapy) programming with optimal stimulation signals, enhanced pulsation, use of exosomes, monitoring via flow cytometry and specialized logistics, in an innovative home care

Biography:

Dr. Ramón Gutierrez is MD by U. de Concepción and pathologist from University of Chile. In USA he holds an MSL; Medical Science Liaison degree from UC Berkeley. In Spain he obtained a Master's Degree in Clinical Oncology from the University of the Basque Country and a Master's Degree in Molecular Oncology from the Center for Biosanitary Studies (CEB) and Rey Juan Carlos University program. He is founder of Bioclas Histopathology Laboratory (bioclas.cl), RECELL Cancer Center in Chile (recell.cl). Biogenica Consortium in Panama (biogénica.org). Currently, is a CSO of Oncocit LLC in USA (oncocit.com) based in Lake Nona medical city of, in Orlando, Fl. His work and research in cancer has been supported by eligible funds from the Chilean government, along with assistance from Universities. He has specialized in the clinical treatment of adoptive immunotherapy for cancer through 3rd generation dendritic cell vaccines, with more than 2,500 applications per year for patients in 24 countries in Latin America